17,396 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, HoldingsChannel.com reports. The institutional investor acquired 17,396 shares of the company’s stock, valued at approximately $248,000.

Several other institutional investors also recently modified their holdings of the stock. Callan Family Office LLC lifted its holdings in shares of Elanco Animal Health by 239.0% during the 2nd quarter. Callan Family Office LLC now owns 166,198 shares of the company’s stock valued at $2,373,000 after purchasing an additional 117,174 shares in the last quarter. US Bancorp DE raised its stake in shares of Elanco Animal Health by 188.4% during the 2nd quarter. US Bancorp DE now owns 42,986 shares of the company’s stock worth $614,000 after purchasing an additional 28,080 shares in the last quarter. KLP Kapitalforvaltning AS raised its stake in shares of Elanco Animal Health by 5.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 101,000 shares of the company’s stock worth $1,442,000 after purchasing an additional 5,000 shares in the last quarter. Petros Family Wealth LLC bought a new stake in shares of Elanco Animal Health during the 2nd quarter worth approximately $149,000. Finally, Bfsg LLC raised its stake in shares of Elanco Animal Health by 5.1% during the 2nd quarter. Bfsg LLC now owns 26,973 shares of the company’s stock worth $385,000 after purchasing an additional 1,321 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $21.77 on Friday. The company has a current ratio of 2.60, a quick ratio of 1.40 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $10.82 billion, a PE ratio of 25.31, a P/E/G ratio of 3.97 and a beta of 1.65. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $21.82. The stock has a 50-day moving average price of $19.23 and a two-hundred day moving average price of $15.08.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the company earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. UBS Group upped their price objective on Elanco Animal Health from $19.00 to $25.00 and gave the company a “buy” rating in a report on Monday. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Elanco Animal Health in a report on Wednesday, October 8th. Wall Street Zen raised Elanco Animal Health from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Finally, Leerink Partners raised Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 price objective on the stock in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.